Welcome to our dedicated page for KONINKLIJKE PHILIPS news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on KONINKLIJKE PHILIPS stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Royal Philips (NYSE: PHG) announced the successful installation of its Lung Suite 3D imaging solution in multiple countries including Belgium, France, Israel, and the UK. This innovation aims to enhance lung cancer diagnosis and minimally-invasive treatment.
Philips Lung Suite provides real-time imaging, facilitating procedures such as biopsy and ablation within the same room. Early clinical trials indicate improved accuracy in diagnosis, with a significant reduction in procedural radiation exposure. Lung cancer remains the leading cause of cancer deaths globally, emphasizing the need for advanced diagnostic solutions.
Royal Philips (NYSE: PHG) announces the agenda for its Annual General Meeting of Shareholders (AGM) 2022, scheduled for May 10, 2022. Key proposals include appointing Herna Verhagen and Sanjay Poonen to the Supervisory Board and re-appointing Dr. Paul Stoffels and Dr. Marc Harrison. Ernst & Young Accountants LLP is proposed to be re-appointed as the company’s auditor. Shareholders can participate virtually and vote online during the meeting. Additional documents related to the AGM are available on the company’s website.
Royal Philips (NYSE: PHG) collaborates with Nuvo Group to enhance maternal care in rural areas through remote pregnancy monitoring. This partnership aims to address the significant lack of maternity care access, with over 2.2 million women living in maternity care deserts across the USA. The pilot program, starting in rural Colorado, will utilize Nuvo's INVU system for prescribed monitoring, allowing expectant mothers to receive essential care remotely. This initiative emerges amid ongoing staffing shortages in healthcare, highlighting the importance of digital solutions in improving maternal health outcomes.
Philips (NYSE: PHG) collaborates with NHS National Services Scotland to enhance breast screening in Scotland through its Vue PACS technology. The initiative aims to tackle a backlog of breast cancer screenings exacerbated by COVID-19, allowing improved access and workflow for screenings across rural areas. Philips’ vendor-neutral system interconnects six screening centers, facilitating image sharing and better patient management. This partnership invites 270,000 women annually for screenings, addressing a significant drop in early-stage diagnoses during the pandemic.
Royal Philips (NYSE: PHG) announced the integration of SecureLink’s critical access management technology with Philips Remote Services to enhance cybersecurity for healthcare providers. This collaboration aims to improve remote technical support by ensuring secure access to medical devices and clinical solutions. The Secure Remote Access Management Service will be available in the USA and Canada from Q3 2022. This expansion aligns with the growing demand for robust cybersecurity solutions in healthcare, especially as cyber threats rise.
On March 15, 2022, Royal Philips (NYSE: PHG) announced FDA clearance for its Philips Capsule Surveillance solution, enhancing patient monitoring capabilities across U.S. healthcare systems. The device aggregates data from multiple medical devices, providing actionable insights to caregivers for timely intervention to prevent patient deterioration. The updated system improves interoperability with existing clinical tools and includes features for eICU and virtual care environments. The rollout is expected in Q2 at select sites, aiming to improve patient outcomes while addressing clinician shortages.
Philips has unveiled new analytics and interoperability solutions at the HIMSS22 Global Health Conference, enhancing its Data Management and Interoperability Solutions portfolio. The upgraded HealthSuite Interoperability platform is cloud-enabled, improving workflow efficiency across imaging departments. Additionally, the Enterprise Performance Analytics – Performance Bridge now includes cardiology department insights, improving operational performance and patient outcomes. Philips aims to leverage healthcare data for enhanced clinical care amid growing demand for data integration.
Philips (NYSE: PHG) showcased its latest health informatics solutions at HIMSS22 in Orlando, focusing on digital transformation and enhancing patient care. The cloud-based Philips HealthSuite platform integrates data streams to support workflow, improving care delivery amidst industry challenges like staffing shortages and cybersecurity threats. Philips received recognition for its contributions, including accolades for its EMR and imaging solutions. The event highlights Philips' commitment to advancing integrated care pathways and outcomes through innovative technologies.
Royal Philips (NYSE: PHG) has announced an expansion of its FDA 510(k) clearance for its Collaboration Live tele-ultrasound technology. This proprietary solution allows clinicians to collaborate in real-time using mobile devices, enhancing diagnostic confidence and efficiency during ultrasound examinations. With the ability to communicate through text, voice, and video, the technology addresses staffing shortages and pandemic-related challenges while improving access to quality care in underserved areas. Peer-reviewed data supporting its efficacy will be presented at the AIUM 2022 Annual Meeting.
On March 10, 2022, Royal Philips' subsidiary, Philips Respironics, updated the status of the ongoing recall of certain sleep and respiratory care products due to health risks associated with PE-PUR foam. The company has registered approximately 2.6 million devices in the U.S. and shipped over 650,000 replacement units. Philips continues working closely with the FDA to enhance recall awareness and has emphasized the risks of using ozone cleaners. Initial tests indicated VOC concentrations are within safe limits, and a recent study found no significant cancer risk for OSA patients using Philips devices.